Jubilant Pharmova arm Salisbury facility gets USFDA EIR
Noida: Jubilant Pharmova Limited has announced that the Company's subsidiary Jubilant Cadista Pharmaceuticals Inc., USA, (Jubilant Cadista)’s solid oral formulations facility at Salisbury, Maryland, USA has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA).
The inspection for the said Facility was conducted in January 2025.
With the receipt of the EIR from the USFDA, the inspection stands successfully closed.
Going forward, the said Facility is not expected to manufacture any products as it has closed manufacturing operations, as was informed in Company’s previous disclosure.
Voluntary Action Indicated (VAI) classification indicates the inspection found objectionable conditions or practices but the agency has determined the facility can voluntarily correct its deficiencies and will not recommend any action.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.